Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

La Jolla Pharmaceutical (NASDAQ:LJPC) Receives Consensus Recommendation of “Hold” from Brokerages

researchsnappy by researchsnappy
December 31, 2019
in Healthcare Research
0
La Jolla Pharmaceutical (NASDAQ:LJPC) Downgraded by HC Wainwright to “Neutral”
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

La Jolla Pharmaceutical logoLa Jolla Pharmaceutical (NASDAQ:LJPC) has received a consensus rating of “Hold” from the nine ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $7.50.

LJPC has been the topic of several research analyst reports. HC Wainwright cut shares of La Jolla Pharmaceutical from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 26th. BidaskClub cut shares of La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, September 27th. Finally, SunTrust Banks cut shares of La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Monday, November 25th.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp boosted its position in shares of La Jolla Pharmaceutical by 2.9% in the third quarter. State Street Corp now owns 427,553 shares of the biopharmaceutical company’s stock worth $3,762,000 after acquiring an additional 11,890 shares during the last quarter. SG Americas Securities LLC raised its holdings in La Jolla Pharmaceutical by 394.8% in the third quarter. SG Americas Securities LLC now owns 375,986 shares of the biopharmaceutical company’s stock valued at $3,309,000 after buying an additional 299,995 shares during the period. Trellus Management Company LLC raised its holdings in La Jolla Pharmaceutical by 127.1% in the third quarter. Trellus Management Company LLC now owns 26,845 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 15,024 shares during the period. Boxer Capital LLC purchased a new position in La Jolla Pharmaceutical in the second quarter valued at approximately $5,319,000. Finally, Morgan Stanley raised its holdings in La Jolla Pharmaceutical by 0.7% in the second quarter. Morgan Stanley now owns 420,862 shares of the biopharmaceutical company’s stock valued at $3,893,000 after buying an additional 2,780 shares during the period. 91.62% of the stock is currently owned by institutional investors and hedge funds.

Shares of La Jolla Pharmaceutical stock traded up $0.05 during mid-day trading on Tuesday, hitting $3.94. 22,447 shares of the stock were exchanged, compared to its average volume of 1,325,549. La Jolla Pharmaceutical has a twelve month low of $2.30 and a twelve month high of $13.90. The stock has a market capitalization of $105.64 million, a price-to-earnings ratio of -0.50 and a beta of 1.84. The company has a 50-day simple moving average of $4.16 and a 200 day simple moving average of $7.82.

La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.03). La Jolla Pharmaceutical had a negative return on equity of 715.11% and a negative net margin of 683.88%. The firm had revenue of $5.71 million for the quarter, compared to analyst estimates of $6.96 million. As a group, equities research analysts expect that La Jolla Pharmaceutical will post -4.43 earnings per share for the current year.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

See Also: Balance Sheet

Analyst Recommendations for La Jolla Pharmaceutical (NASDAQ:LJPC)



Receive News & Ratings for La Jolla Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.


Previous Post

Antirotavirus IgA seroconversion rates in children who receive concomitant oral poliovirus vaccine: A secondary, pooled analysis of Phase II and III trial data from 33 countries.

Next Post

Congressman McCarthy expands funding for Valley Fever research – Kern Valley Sun

Next Post
Congressman McCarthy expands funding for Valley Fever research – Kern Valley Sun

Congressman McCarthy expands funding for Valley Fever research – Kern Valley Sun

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News

Pa. Republicans reconsider Pitt funding over fetal tissue research, college voucher program

Arthur Pharma Closes Series A Financing Round

YouTube and the Achilles Tendon: An Analysis of Internet Information Reliability and Content Quality

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2022 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2022 researchsnappy.com